Advertisement

Immunotherapy for Obesity

  • Tatsuhiko AzegamiEmail author
  • Hiroshi Itoh
Chapter

Abstract

Obesity prevalence continues to increase in both adults and children worldwide and greatly contributes to increased morbidity and mortality. Although there are some anti-obesity drugs globally available for clinical use, their inadequate effectiveness coupled with safety concerns sometimes discourage the widespread use of anti-obesity medication. Because of its prolonged therapeutic effect and low frequency of administration, a therapeutic vaccine may be an attractive strategy for the prevention and treatment of obesity. Over the last two decades, several attempts have been made to develop vaccines for the control of obesity. Animal studies have shown that vaccines targeting ghrelin, glucose-dependent insulinotropic polypeptide, adipocytes, somatostatin, and adenovirus 36 successfully led to a reduction in weight gain without serious adverse effects. This chapter provides an overview of recent progress toward a therapeutic vaccine against obesity.

Keywords

Obesity Ghrelin Glucose-dependent insulinotropic polypeptide Adipocyte Somatostatin Adenovirus 36 

Notes

Acknowledgments

This work was supported in part by the Mochida Memorial Foundation for Medical and Pharmaceutical Research.

Conflict of Interest

The authors have no conflicts of interest to declare.

References

  1. Ambuhl PM, Tissot AC, Fulurija A et al (2007) A vaccine for hypertension based on virus-like particles: preclinical efficacy and phase I safety and immunogenicity. J Hypertens 25:63–72PubMedCrossRefPubMedCentralGoogle Scholar
  2. Andrade S, Pinho F, Ribeiro AM et al (2013) Immunization against active ghrelin using virus-like particles for obesity treatment. Curr Pharm Des 19:6551–6558PubMedPubMedCentralCrossRefGoogle Scholar
  3. Asakawa A, Inui A, Fujimiya M et al (2005) Stomach regulates energy balance via acylated ghrelin and desacyl ghrelin. Gut 54:18–24PubMedPubMedCentralCrossRefGoogle Scholar
  4. Atkinson RL, Dhurandhar NV, Allison DB et al (2005) Human adenovirus-36 is associated with increased body weight and paradoxical reduction of serum lipids. Int J Obes 29:281–286CrossRefGoogle Scholar
  5. Azegami T, Yuki Y, Sawada S et al (2017) Nanogel-based nasal ghrelin vaccine prevents obesity. Mucosal Immunol 10:1351–1360PubMedCrossRefPubMedCentralGoogle Scholar
  6. Azegami T, Yuki Y, Nakahashi R et al (2018) Nanogel-based nasal vaccines for infectious and lifestyle-related diseases. Mol Immunol 98:19–24PubMedCrossRefPubMedCentralGoogle Scholar
  7. Baum HB, Biller BM, Finkelstein JS et al (1996) Effects of physiologic growth hormone therapy on bone density and body composition in patients with adult-onset growth hormone deficiency. A randomized, placebo-controlled trial. Ann Intern Med 125:883–890PubMedCrossRefPubMedCentralGoogle Scholar
  8. Bourinbaiar AS, Jirathitikal V (2010) Effect of oral immunization with pooled antigens derived from adipose tissue on atherosclerosis and obesity indices. Vaccine 28:2763–2768PubMedCrossRefPubMedCentralGoogle Scholar
  9. Bray GA, Fruhbeck G, Ryan DH et al (2016) Management of obesity. Lancet 387:1947–1956PubMedCrossRefPubMedCentralGoogle Scholar
  10. Date Y, Shimbara T, Koda S et al (2006) Peripheral ghrelin transmits orexigenic signals through the noradrenergic pathway from the hindbrain to the hypothalamus. Cell Metab 4:323–331PubMedCrossRefPubMedCentralGoogle Scholar
  11. Dhurandhar NV, Whigham LD, Abbott DH et al (2002) Human adenovirus Ad-36 promotes weight gain in male rhesus and marmoset monkeys. J Nutr 132:3155–3160PubMedCrossRefPubMedCentralGoogle Scholar
  12. Faria AC, Veldhuis JD, Thorner MO et al (1989) Half-time of endogenous growth hormone (GH) disappearance in normal man after stimulation of GH secretion by GH-releasing hormone and suppression with somatostatin. J Clin Endocrinol Metab 68:535–541PubMedCrossRefPubMedCentralGoogle Scholar
  13. Flegal KM, Kit BK, Orpana H et al (2013) Association of all-cause mortality with overweight and obesity using standard body mass index categories: a systematic review and meta-analysis. JAMA 309:71–82PubMedPubMedCentralCrossRefGoogle Scholar
  14. Fulurija A, Lutz TA, Sladko K et al (2008) Vaccination against GIP for the treatment of obesity. PLoS One 3:e3163PubMedPubMedCentralCrossRefGoogle Scholar
  15. Ghelardoni S, Carnicelli V, Frascarelli S et al (2006) Ghrelin tissue distribution: comparison between gene and protein expression. J Endocrinol Investig 29:115–121CrossRefGoogle Scholar
  16. Haffer KN (2012) Effects of novel vaccines on weight loss in diet-induced-obese (DIO) mice. J Anim Sci Biotechnol 3:21PubMedPubMedCentralCrossRefGoogle Scholar
  17. Heymsfield SB, Wadden TA (2017) Mechanisms, pathophysiology, and management of obesity. N Engl J Med 376:254–266PubMedCrossRefPubMedCentralGoogle Scholar
  18. Kenchaiah S, Evans JC, Levy D et al (2002) Obesity and the risk of heart failure. N Engl J Med 347:305–313PubMedCrossRefGoogle Scholar
  19. Kim KR, Nam SY, Song YD et al (1999) Low-dose growth hormone treatment with diet restriction accelerates body fat loss, exerts anabolic effect and improves growth hormone secretory dysfunction in obese adults. Horm Res 51:78–84PubMedGoogle Scholar
  20. Kojima M, Hosoda H, Date Y et al (1999) Ghrelin is a growth-hormone-releasing acylated peptide from stomach. Nature 402:656–660PubMedCrossRefPubMedCentralGoogle Scholar
  21. Kushnir N, Streatfield SJ, Yusibov V (2012) Virus-like particles as a highly efficient vaccine platform: diversity of targets and production systems and advances in clinical development. Vaccine 31:58–83PubMedCrossRefPubMedCentralGoogle Scholar
  22. Lai QG, Jiang BQ, Zhou XH et al (2010) The effects and mechanism of xenogeneic adipocyte vaccine for the prevention of obesity in rats. J Int Med Res 38:1700–1707PubMedCrossRefPubMedCentralGoogle Scholar
  23. Lamichhane A, Azegami T, Kiyono H (2014) The mucosal immune system for vaccine development. Vaccine 32:6711–6723PubMedCrossRefPubMedCentralGoogle Scholar
  24. Lyons MJ, Faust IM, Hemmes RB et al (1982) A virally induced obesity syndrome in mice. Science 216:82–85PubMedCrossRefPubMedCentralGoogle Scholar
  25. Maurer P, Jennings GT, Willers J et al (2005) A therapeutic vaccine for nicotine dependence: preclinical efficacy, and Phase I safety and immunogenicity. Eur J Immunol 35:2031–2040PubMedCrossRefPubMedCentralGoogle Scholar
  26. McClean PL, Irwin N, Cassidy RS et al (2007) GIP receptor antagonism reverses obesity, insulin resistance, and associated metabolic disturbances induced in mice by prolonged consumption of high-fat diet. Am J Physiol Endocrinol Metab 293:E1746–E1755PubMedCrossRefPubMedCentralGoogle Scholar
  27. Miyawaki K, Yamada Y, Ban N et al (2002) Inhibition of gastric inhibitory polypeptide signaling prevents obesity. Nat Med 8:738–742PubMedCrossRefPubMedCentralGoogle Scholar
  28. Na HN, Nam JH (2014) Proof-of-concept for a virus-induced obesity vaccine; vaccination against the obesity agent adenovirus 36. Int J Obes 38:1470–1474CrossRefGoogle Scholar
  29. Nakazato M, Murakami N, Date Y et al (2001) A role for ghrelin in the central regulation of feeding. Nature 409:194–198PubMedCrossRefPubMedCentralGoogle Scholar
  30. Nochi T, Yuki Y, Takahashi H et al (2010) Nanogel antigenic protein-delivery system for adjuvant-free intranasal vaccines. Nat Mater 9:572–578PubMedCrossRefPubMedCentralGoogle Scholar
  31. Renehan AG, Tyson M, Egger M et al (2008) Body-mass index and incidence of cancer: a systematic review and meta-analysis of prospective observational studies. Lancet 371:569–578PubMedCrossRefPubMedCentralGoogle Scholar
  32. Rogers PM, Fusinski KA, Rathod MA et al (2008) Human adenovirus Ad-36 induces adipogenesis via its E4 orf-1 gene. Int J Obes 32:397–406CrossRefGoogle Scholar
  33. Sadry SA, Drucker DJ (2013) Emerging combinatorial hormone therapies for the treatment of obesity and T2DM. Nat Rev Endocrinol 9:425–433PubMedCrossRefPubMedCentralGoogle Scholar
  34. Srivastava G, Apovian CM (2018) Current pharmacotherapy for obesity. Nat Rev Endocrinol 14:12–24PubMedCrossRefPubMedCentralGoogle Scholar
  35. Tschop M, Smiley DL, Heiman ML (2000) Ghrelin induces adiposity in rodents. Nature 407:908–913PubMedCrossRefPubMedCentralGoogle Scholar
  36. Vangipuram SD, Sheele J, Atkinson RL et al (2004) A human adenovirus enhances preadipocyte differentiation. Obes Res 12:770–777PubMedCrossRefPubMedCentralGoogle Scholar
  37. Vangipuram SD, Yu M, Tian J et al (2007) Adipogenic human adenovirus-36 reduces leptin expression and secretion and increases glucose uptake by fat cells. Int J Obes 31:87–96CrossRefGoogle Scholar
  38. Vivante A, Golan E, Tzur D et al (2012) Body mass index in 1.2 million adolescents and risk for end-stage renal disease. Arch Intern Med 172:1644–1650PubMedPubMedCentralCrossRefGoogle Scholar
  39. Vizcarra JA, Kirby JD, Kim SK et al (2007) Active immunization against ghrelin decreases weight gain and alters plasma concentrations of growth hormone in growing pigs. Domest Anim Endocrinol 33:176–189PubMedCrossRefPubMedCentralGoogle Scholar
  40. Wadden TA, Webb VL, Moran CH et al (2012) Lifestyle modification for obesity: new developments in diet, physical activity, and behavior therapy. Circulation 125:1157–1170PubMedPubMedCentralCrossRefGoogle Scholar
  41. Wang YC, McPherson K, Marsh T et al (2011) Health and economic burden of the projected obesity trends in the USA and the UK. Lancet 378:815–825PubMedCrossRefPubMedCentralGoogle Scholar
  42. Wilson PW, D’Agostino RB, Sullivan L et al (2002) Overweight and obesity as determinants of cardiovascular risk: the Framingham experience. Arch Intern Med 162:1867–1872PubMedCrossRefPubMedCentralGoogle Scholar
  43. Wortley KE, Anderson KD, Garcia K et al (2004) Genetic deletion of ghrelin does not decrease food intake but influences metabolic fuel preference. Proc Natl Acad Sci U S A 101:8227–8232PubMedPubMedCentralCrossRefGoogle Scholar
  44. Yang J, Brown MS, Liang G et al (2008) Identification of the acyltransferase that octanoylates ghrelin, an appetite-stimulating peptide hormone. Cell 132:387–396PubMedCrossRefPubMedCentralGoogle Scholar
  45. Zigman JM, Nakano Y, Coppari R et al (2005) Mice lacking ghrelin receptors resist the development of diet-induced obesity. J Clin Invest 115:3564–3572PubMedPubMedCentralCrossRefGoogle Scholar
  46. Zorrilla EP, Iwasaki S, Moss JA et al (2006) Vaccination against weight gain. Proc Natl Acad Sci U S A 103:13226–13231PubMedPubMedCentralCrossRefGoogle Scholar

Copyright information

© Springer Nature Singapore Pte Ltd. 2019

Authors and Affiliations

  1. 1.Health CenterKeio UniversityYokohamaJapan
  2. 2.Department of Internal MedicineSchool of Medicine, Keio UniversityTokyoJapan

Personalised recommendations